SLN250117C5000
- 3.80
- 0.000.00%
Silence Therapeutics Newsroom
Top 3 Health Care Stocks That May Explode In Q4
Insider Traders Lose UK£124k As Silence Therapeutics Drops
Institutional Owners May Take Dramatic Actions as Silence Therapeutics Plc's (NASDAQ:SLN) Recent 22% Drop Adds to One-year Losses
European Equities Traded in the US as American Depositary Lower in Tuesday Trading
The Analyst Landscape: 6 Takes On Silence Therapeutics
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)
Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Silence Therapeutics Advances Promising SiRNA Therapy for PV
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Express News | Silence Therapeutics PLC : Jefferies Cuts Target Price to $31 From $38
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics Analyst Ratings
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Top 3 Health Care Stocks You'll Regret Missing In Q4
Silence Therapeutics Showcases Promising Phase 2 Results
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose